Daily Stock Analysis, FOLD, Amicus Therapeutics Inc, priceseries

Amicus Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
10.11
Close
10.11
High
10.19
Low
9.62
Previous Close
10.02
Daily Price Gain
0.09
YTD High
14.62
YTD High Date
Apr 8, 2019
YTD Low
7.11
YTD Low Date
Oct 2, 2019
YTD Price Change
0.07
YTD Gain
0.70%
52 Week High
14.62
52 Week High Date
Apr 8, 2019
52 Week Low
7.11
52 Week Low Date
Oct 2, 2019
52 Week Price Change
0.19
52 Week Gain
1.92%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 27. 2017
6.43
Mar 7. 2017
7.04
6 Trading Days
9.49%
Link
LONG
Apr 19. 2017
7.18
May 3. 2017
7.56
10 Trading Days
5.24%
Link
LONG
Dec 20. 2017
13.50
Jan 8. 2018
14.49
11 Trading Days
7.35%
Link
LONG
May 14. 2018
14.24
May 23. 2018
15.38
7 Trading Days
8.01%
Link
LONG
Dec 31. 2018
9.58
Jan 22. 2019
11.75
14 Trading Days
22.67%
Link
LONG
Feb 22. 2019
11.75
Mar 19. 2019
13.47
17 Trading Days
14.64%
Link
LONG
Nov 7. 2019
8.92
Dec 5. 2019
10.27
19 Trading Days
15.14%
Link
Company Information
Stock Symbol
FOLD
Exchange
NasdaqGM
Company URL
http://www.amicusrx.com
Company Phone
(609) 662-2000
CEO
John Francis Crowley
Headquarters
New Jersey
Business Address
1 CEDAR BROOK DRIVE, CRANBURY, NJ 08512
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001178879
About

Amicus Therapeutics, Inc. is a biopharmaceutical company focuses on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for the treatment of rare diseases, pharmacological chaperones are a novel, first-in-class approach to treating a broad range of diseases, including lysosomal storage disorders and diseases of neurodegeneration. Amicus develops pharmacological chaperones oral therapies that bind to and stabilize the affected proteins, restoring their shape, proper trafficking, and biological activity. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Description

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.